Lung Cancer

Advanced or Metastatic 1st Line

A Randomized, Open-Label, Multicenter, Phase II Trial Comparing Veliparib Plus Carboplatin and Paclitaxel  vs. Investigators Choice of Standard Chemotherapy in Advanced Non-Squamous Non Small Cell Lung Cancer (NSCLC) pts who are Current or Former Smokers.  Abbvie – M14-359   www.VELASTUDY.com

A Multicenter, Randomized, Double-Blind Phase III Trial to evaluate the Efficacy and Safety of BI 695502 plus Chemotherapy versus Avastin®  Plus Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer.  -  Boehringer Ingelheim – 1302.5

An Open Label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib (Gefitinib is outside US only) in First Line Treatment of Patients with Stage IIIB / IV Non-Small Cell Lung Cancer Tumors with EGFR Activating Mutations.  Astellas 8273-CL-0302 “SOLAR Study” www.thesolarstudy.com 

A Master Protocol of Phase 1-2 Studies of Nivolumab in Advanced Non Small Cell Lung Cancer using Nivolumab as Maintenance after Induction Chemotherapy or as 1st Line Treatment Alone  or in Combination with Standard of Care Therapies.   Bristol Myers Squibb – CA209370  “Checkmate 370” Study

Advanced Stage IV only - 2nd Line

A Randomized Phase 3 Study of Abemaciclib plus BSC (best supportive care) vs Erlotinib plus BSC (best supportive care) in Patients with Stage IV (NSCLC) Non-Small Cell Lung Cancer with a detectable KRAS Mutation who have progressed after Platinum based Chemotherapy  - Eli Lilly I3Y-MC-JPBK - The “JUNIPER" Study

Advanced or Metastatic 3rd Line

A Phase III, Open-Label, Randomized, Multi-Center, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, vs. Standard of Care in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB / IV) who Have Received at Least two Prior Systemic Treatment Regimens Including One Platinum-Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements.  AstraZeneca D4191C00004 – The “ARCTIC” Study